BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 12654432)

  • 1. Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: relationship to therapeutic response-a preliminary report.
    Dehdashti F; Grigsby PW; Mintun MA; Lewis JS; Siegel BA; Welch MJ
    Int J Radiat Oncol Biol Phys; 2003 Apr; 55(5):1233-8. PubMed ID: 12654432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing tumor hypoxia in cervical cancer by PET with 60Cu-labeled diacetyl-bis(N4-methylthiosemicarbazone).
    Dehdashti F; Grigsby PW; Lewis JS; Laforest R; Siegel BA; Welch MJ
    J Nucl Med; 2008 Feb; 49(2):201-5. PubMed ID: 18199612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM.
    Dehdashti F; Mintun MA; Lewis JS; Bradley J; Govindan R; Laforest R; Welch MJ; Siegel BA
    Eur J Nucl Med Mol Imaging; 2003 Jun; 30(6):844-50. PubMed ID: 12692685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor hypoxia detected by positron emission tomography with 60Cu-ATSM as a predictor of response and survival in patients undergoing Neoadjuvant chemoradiotherapy for rectal carcinoma: a pilot study.
    Dietz DW; Dehdashti F; Grigsby PW; Malyapa RS; Myerson RJ; Picus J; Ritter J; Lewis JS; Welch MJ; Siegel BA
    Dis Colon Rectum; 2008 Nov; 51(11):1641-8. PubMed ID: 18682881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of molecular markers of hypoxia and imaging with (60)Cu-ATSM in cancer of the uterine cervix.
    Grigsby PW; Malyapa RS; Higashikubo R; Schwarz JK; Welch MJ; Huettner PC; Dehdashti F
    Mol Imaging Biol; 2007; 9(5):278-83. PubMed ID: 17431727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing tumor hypoxia in head and neck cancer by PET with ⁶²Cu-diacetyl-bis(N⁴-methylthiosemicarbazone).
    Sato Y; Tsujikawa T; Oh M; Mori T; Kiyono Y; Fujieda S; Kimura H; Okazawa H
    Clin Nucl Med; 2014 Dec; 39(12):1027-32. PubMed ID: 25140555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy.
    Chao KS; Bosch WR; Mutic S; Lewis JS; Dehdashti F; Mintun MA; Dempsey JF; Perez CA; Purdy JA; Welch MJ
    Int J Radiat Oncol Biol Phys; 2001 Mar; 49(4):1171-82. PubMed ID: 11240261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathophysiologic correlation between 62Cu-ATSM and 18F-FDG in lung cancer.
    Lohith TG; Kudo T; Demura Y; Umeda Y; Kiyono Y; Fujibayashi Y; Okazawa H
    J Nucl Med; 2009 Dec; 50(12):1948-53. PubMed ID: 19910425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of hypoxic PET using (18)F-FAZA and (62)Cu-ATSM in non-small-cell lung cancer.
    Kinoshita T; Fujii H; Hayashi Y; Kamiyama I; Ohtsuka T; Asamura H
    Lung Cancer; 2016 Jan; 91():56-66. PubMed ID: 26711935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autoradiographic and small-animal PET comparisons between (18)F-FMISO, (18)F-FDG, (18)F-FLT and the hypoxic selective (64)Cu-ATSM in a rodent model of cancer.
    Dence CS; Ponde DE; Welch MJ; Lewis JS
    Nucl Med Biol; 2008 Aug; 35(6):713-20. PubMed ID: 18678357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic implications of
    Toriihara A; Ohtake M; Tateishi K; Hino-Shishikura A; Yoneyama T; Kitazume Y; Inoue T; Kawahara N; Tateishi U
    Ann Nucl Med; 2018 May; 32(4):264-271. PubMed ID: 29453680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose painting based on tumor uptake of Cu-ATSM and FDG: a comparative study.
    Clausen MM; Hansen AE; Lundemann M; Hollensen C; Pommer T; Munck Af Rosenschöld P; Kristensen AT; Kjær A; McEvoy FJ; Engelholm SA
    Radiat Oncol; 2014 Oct; 9():228. PubMed ID: 25319766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An imaging comparison of 64Cu-ATSM and 60Cu-ATSM in cancer of the uterine cervix.
    Lewis JS; Laforest R; Dehdashti F; Grigsby PW; Welch MJ; Siegel BA
    J Nucl Med; 2008 Jul; 49(7):1177-82. PubMed ID: 18552145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: Comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models.
    O'Donoghue JA; Zanzonico P; Pugachev A; Wen B; Smith-Jones P; Cai S; Burnazi E; Finn RD; Burgman P; Ruan S; Lewis JS; Welch MJ; Ling CC; Humm JL
    Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1493-502. PubMed ID: 15817355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of tumor hypoxia by 62Cu-ATSM PET/CT as a predictor of response in head and neck cancer: a pilot study.
    Minagawa Y; Shizukuishi K; Koike I; Horiuchi C; Watanuki K; Hata M; Omura M; Odagiri K; Tohnai I; Inoue T; Tateishi U
    Ann Nucl Med; 2011 Jun; 25(5):339-45. PubMed ID: 21327756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Different distribution of (62) Cu ATSM and (18)F-FDG in head and neck cancers.
    Kositwattanarerk A; Oh M; Kudo T; Kiyono Y; Mori T; Kimura Y; Maruyama R; Fujibayashi Y; Fujieda S; Okazawa H
    Clin Nucl Med; 2012 Mar; 37(3):252-7. PubMed ID: 22310251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multimodality functional imaging of spontaneous canine tumors using 64Cu-ATSM and 18FDG PET/CT and dynamic contrast enhanced perfusion CT.
    Hansen AE; Kristensen AT; Law I; McEvoy FJ; Kjær A; Engelholm SA
    Radiother Oncol; 2012 Mar; 102(3):424-8. PubMed ID: 22119225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spatiotemporal stability of Cu-ATSM and FLT positron emission tomography distributions during radiation therapy.
    Bradshaw TJ; Yip S; Jallow N; Forrest LJ; Jeraj R
    Int J Radiat Oncol Biol Phys; 2014 Jun; 89(2):399-405. PubMed ID: 24685446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intertumoral differences in hypoxia selectivity of the PET imaging agent 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone).
    Yuan H; Schroeder T; Bowsher JE; Hedlund LW; Wong T; Dewhirst MW
    J Nucl Med; 2006 Jun; 47(6):989-98. PubMed ID: 16741309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of 62Cu-diacetyl-bis (N4-methylthiosemicarbazone) PET imaging to predict highly malignant tumor grades and hypoxia-inducible factor-1α expression in patients with glioma.
    Tateishi K; Tateishi U; Sato M; Yamanaka S; Kanno H; Murata H; Inoue T; Kawahara N
    AJNR Am J Neuroradiol; 2013 Jan; 34(1):92-9. PubMed ID: 22700754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.